Follicle stimulating hormone receptor (FSHR) and luteinizing hormone receptor (LHCGR) were demonstrated to impact upon survival of patients suffering from epithelial ovarian cancer (EOC). Though structure wise the G-protein coupled estrogen receptor (GPER/GPR30) is related to FSHR/LHCGR, its prognostic impact in EOC remains controversial. We recently found that FSHR negative patients represent ...

This study explored the effects of GnRH agonist (GnRHa) immunity on expression of FSHR mRNA in pituitary and FSHR protein in uteri, and also confirmed its efficacy on uterine development. 42 prepuberty and non cyclic ewes were assigned to 6 experimental groups (EG) during anestrus season. Animals in EG-I, EG-II and EG-III were subcutaneously injected with 200, 300 and 400 μg alarelin antigens (...

background: increasing serum levels of uric acid (sua) after menopause in women brought up a hypothesis that estrogenic effect may protectively regulate sua. estrogenic effect is a major etiology of uterine fibroids and fibrocystic breast disease. the study aimed to explore sua among patients suffering from these diseases to enhance the hypothesis. methods: overall , 1349 female participants we...

Follicle-Stimulating Hormone Receptor (FSHR) -29G/A polymorphism (rs1394205) was reported to modulate gene expression and reproductive parameters in women, but data in men is limited. We aimed to bring evidence to the effect of FSHR -29G/A variants in men. In Baltic young male cohort (n = 982; Estonians, Latvians, Lithuanians; aged 20.2 ± 2.0 years), the FSHR -29 A-allele was significantly asso...

Adoptive transfer of T cells engineered to express chimeric immunoreceptors is an effective strategy to treat hematologic cancers; however, the use of this type of therapy for solid cancers, such as ovarian cancer, remains challenging because a safe and effective immunotherapeutic target has not yet been identified. Here, we constructed and evaluated a novel redirected T-cell-based immunotherap...

this study explored the effects of gnrh agonist (gnrha) immunity on expression of fshr mrna in pituitary and fshr protein in uteri, and also confirmed its efficacy on uterine development. 42 prepuberty and non cyclic ewes were assigned to 6 experimental groups (eg) during anestrus season. animals in eg-i, eg-ii and eg-iii were subcutaneously injected with 200, 300 and 400 μg alarelin antigens (...

BACKGROUND Inactivating mutations of the FSH receptor (FSHR) are a rare cause of hypergonadotrophic hypogonadism in women. Only one patient with primary amenorrhoea due to an FSHR gene mutation has been reported outside of Finland, where the prevalence of Ala189Val mutations is particularly high. METHODS AND RESULTS Here, we describe the clinical, molecular genetic and functional characterist...

INTRODUCTION In normal conditions follicle-stimulating hormone receptors (FSHR) are expressed in the ovary and the testis. They can also be expressed in gonadal tumors. However, recently we have found FSHR immunostaining in pituitary adenomas, adrenal tumors and neuroendocrine tumors (carcinoids). The aim of this study was to determine whether the same occurs in thyroid tumors. MATERIAL AND M...

Expression of follicle-stimulation hormone receptor (FSHR) is confined to gonads and at low levels to some extragonadal tissues like human umbilical vein endothelial cells (HUVEC). FSH-FSHR signaling was shown to promote HUVEC angiogenesis and thereafter suggested to have an influential role in pregnancy. We revisited hereby the expression and functionality of FSHR in HUVECs angiogenesis, and w...

BACKGROUND In normal conditions FSHR are expressed in granulosa cells of the ovary and Sertoli cells of the testis. They can be expressed also in gonadal tumours. However, recently the expression of FSHR was found in tumoral cells and intra-tumoral blood vessels of many other tumours, including thyroid tumours. Aim of this study was to see whether the expression of FSHR can be useful in the dif...